Skip to main content
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMLX ISIN · US0321085088 US Manufacturing
Open in API
Filings indexed 383 across all filing types
Latest filing 2024-08-08 Interim / Quarterly Rep…
Country US United States of America
Listing US AMLX

About Amylyx Pharmaceuticals, Inc.

https://www.amylyx.com/

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2024
2024-08-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2024, by Amylyx Pharmaceuticals, Inc. It announces the issuance of a press release regarding financial results for the fiscal quarter ended June 30, 2024. The document itself does not contain the financial results but references an attached press release (Exhibit 99.1) that contains the financial results. The text explicitly states that the information is furnished and not filed, and it is a current report rather than a full quarterly or annual report. The document length is 3498 characters, which is relatively short and consistent with an earnings release announcement rather than a full report. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2024-08-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 9, 2024, by Amylyx Pharmaceuticals, Inc. It reports the completion of an acquisition of assets (Avexitide) from Eiger BioPharmaceuticals, Inc. The content focuses on the acquisition transaction details, including the asset purchase agreement, court approval, and closing of the sale. There are no financial statements or detailed financial performance data presented. The document is a current report on a material event (asset acquisition) rather than a full annual or quarterly report, earnings release, or other financial disclosure. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement of a significant corporate event that does not fit into more specific categories like M&A filings (which are typically merger or tender offer related forms) or Capital/Financing Updates (which focus on fundraising or capital structure changes). Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-07-10 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-07-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically an Asset Purchase Agreement, including details about the transaction and related bankruptcy court approval. There are no financial statements or detailed financial performance data included, only a description of the transaction and related legal conditions. The document also includes the Asset Purchase Agreement as an exhibit but does not contain the full agreement text in the main body. This type of filing is best classified as a Regulatory Filing (RNS) because it is a current report announcing a material event rather than a full financial report or other specific category. The document length (6849 characters) and content confirm it is not a report publication announcement or a certification. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2024-06-21 English
4
Director's Dealing
2024-06-07 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.